Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 275

1.

Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?

Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, Giraud F, Wislez M, Damotte D, Lupo A, Vidal M, Alexandre J, Goldwasser F, Tod M, Blanchet B.

Cancers (Basel). 2019 Nov 13;11(11). pii: E1784. doi: 10.3390/cancers11111784.

2.

Systematic review of artesunate pharmacokinetics: Implication for treatment of resistant malaria.

Kouakou YI, Tod M, Leboucher G, Lavoignat A, Bonnot G, Bienvenu AL, Picot S.

Int J Infect Dis. 2019 Dec;89:30-44. doi: 10.1016/j.ijid.2019.08.030. Epub 2019 Sep 3.

3.

Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies.

Corbaux P, El-Madani M, Tod M, Péron J, Maillet D, Lopez J, Freyer G, You B.

Eur J Cancer. 2019 Oct;120:40-46. doi: 10.1016/j.ejca.2019.08.002. Epub 2019 Aug 31. Review.

PMID:
31479946
4.

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.

Pierrillas PB, Henin E, Ball K, Ogier J, Amiel M, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

Drug Metab Dispos. 2019 Jun;47(6):648-656. doi: 10.1124/dmd.118.085605. Epub 2019 Apr 2.

PMID:
30940629
5.

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.

Colomban O, Tod M, Leary A, Ray-Coquard I, Lortholary A, Hardy-Bessard AC, Pfisterer J, Du Bois A, Kurzeder C, Burges A, Péron J, Freyer G, You B.

Clin Cancer Res. 2019 Sep 1;25(17):5342-5350. doi: 10.1158/1078-0432.CCR-18-3335. Epub 2019 Apr 1.

PMID:
30936122
6.

Thesaurus for off-label indications for systemic antifungal agents.

Bienvenu AL, Aussedat M, Maldonado F, Kavafian R, Barbieri C, Tod M, Paillet C, Juillard L, Chidiac C, Leboucher G.

Med Mal Infect. 2019 Jun;49(4):275-280. doi: 10.1016/j.medmal.2018.11.003. Epub 2018 Dec 4.

PMID:
30527972
7.

Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice.

Pierrillas PB, Henin E, Ogier J, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

J Pharmacol Exp Ther. 2018 Dec;367(3):414-424. doi: 10.1124/jpet.118.251694. Epub 2018 Sep 18.

PMID:
30228112
8.

A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.

Tod M, Goutelle S, Bleyzac N, Bourguignon L.

Clin Pharmacokinet. 2019 Apr;58(4):503-523. doi: 10.1007/s40262-018-0711-0.

PMID:
30194612
9.

Prospective Cohort Study of the Tolerability of Prosthetic Joint Infection Empirical Antimicrobial Therapy.

Triffault-Fillit C, Valour F, Guillo R, Tod M, Goutelle S, Lustig S, Fessy MH, Chidiac C, Ferry T; Lyon BJI Study Group.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00163-18. doi: 10.1128/AAC.00163-18. Print 2018 Oct.

10.

Toxicokinetics and tolerance of a high energy material 3,4,5-trinitropyrazole (TNP) in mice.

Guyot L, Honorat M, Jacob G, Bardel C, Tod M, Puisieux A, Guitton J, Payen L.

Toxicol Appl Pharmacol. 2018 Sep 15;355:103-111. doi: 10.1016/j.taap.2018.06.023. Epub 2018 Jun 26.

PMID:
29959026
11.

Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.

Le Saux O, Bourmaud A, Rioufol C, Colomban O, Guitton J, Schwiertz V, Regnier V, You B, Ranchon F, Maraval-Gaget R, Girard P, Chauvin F, Freyer G, Tod M, Henin E, Trillet-Lenoir V.

Cancer Chemother Pharmacol. 2018 Aug;82(2):319-327. doi: 10.1007/s00280-018-3612-x. Epub 2018 Jun 15.

PMID:
29948022
12.

Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.

Fermier N, Bourguignon L, Goutelle S, Bleyzac N, Tod M.

Clin Pharmacokinet. 2018 Dec;57(12):1581-1591. doi: 10.1007/s40262-018-0651-8.

PMID:
29572664
13.

In Silico Evaluation of Pharmacokinetic Optimization for Antimitogram-Based Clinical Trials.

Haviari S, You B, Tod M.

Cancer Res. 2018 Apr 1;78(7):1873-1882. doi: 10.1158/0008-5472.CAN-17-1710. Epub 2018 Jan 9.

14.

Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.

Ducoulombier S, Golfier F, Colomban O, Benayoun D, Bolze PA, Tod M, You B.

Anticancer Res. 2017 Dec;37(12):6879-6886.

PMID:
29187468
15.

Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients.

Chevillard L, Sabo N, Tod M, Labat L, Chasport C, Chevaleyre C, Thibaut F, Barré J, Azuar J, Questel F, Vorspan F, Bloch V, Bellivier F, Granger B, Barrault C, Declèves X.

Fundam Clin Pharmacol. 2018 Apr;32(2):239-248. doi: 10.1111/fcp.12330. Epub 2017 Nov 23.

PMID:
29091319
16.

Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism.

Cerruti L, Bleyzac N, Tod M.

Clin Pharmacokinet. 2018 Jul;57(7):831-841. doi: 10.1007/s40262-017-0596-3.

PMID:
28889370
17.

Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.

Peigné S, Chhun S, Tod M, Rey E, Rodrigues C, Chiron C, Pons G, Jullien V.

Clin Pharmacokinet. 2018 Jun;57(6):739-748. doi: 10.1007/s40262-017-0592-7.

PMID:
28819726
18.

Mechanisms of drug-drug interaction between rifampicin and fusidic acid.

Bel F, Bourguignon L, Tod M, Ferry T, Goutelle S.

Br J Clin Pharmacol. 2017 Aug;83(8):1862-1864. doi: 10.1111/bcp.13277. Epub 2017 Apr 12. No abstract available.

19.

[How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4].

Bensalah N, Garcia S, Rose FX, Bedouch P, Conort O, Juste M, Roubille R, Allenet B, Tod M, Charpiat B.

Prog Urol. 2017 Apr;27(5):275-282. doi: 10.1016/j.purol.2017.02.003. Epub 2017 Mar 30. Review. French.

PMID:
28365198
20.

Respiratory depression related to multiple drug-drug interactions precipitated by a fluconazole loading dose in a patient treated with oxycodone.

Charpiat B, Tod M, Darnis B, Boulay G, Gagnieu MC, Mabrut JY.

Eur J Clin Pharmacol. 2017 Jun;73(6):787-788. doi: 10.1007/s00228-017-2215-5. Epub 2017 Mar 9. No abstract available.

PMID:
28280888
21.

Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.

Hénin E, Honorat M, Guitton J, Di Pietro A, Payen L, Tod M.

Biopharm Drug Dispos. 2017 Jul;38(5):351-362. doi: 10.1002/bdd.2069. Epub 2017 Mar 23.

PMID:
28207160
22.

EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.

El-Madani M, Colomban O, Tod M, Maillet D, Peron J, Rodriguez-Lafrasse C, Badary OA, Valette PJ, Lefort T, Cassier P, El-Shenawy SM, El-Demerdash E, Hommel-Fontaine J, Guitton J, Gagnieu MC, Ibrahim BM, Barrois C, Freyer G, You B.

Future Oncol. 2017 Apr;13(8):679-693. doi: 10.2217/fon-2016-0357. Epub 2017 Jan 12.

PMID:
28076966
23.

Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?

Tod M, Goutelle S, Bourguignon L, Bleyzac N.

CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):226. doi: 10.1002/psp4.12164. Epub 2017 Apr 11. No abstract available.

24.

A Model for Predicting the Interindividual Variability of Drug-Drug Interactions.

Tod M, Bourguignon L, Bleyzac N, Goutelle S.

AAPS J. 2017 Mar;19(2):497-509. doi: 10.1208/s12248-016-0021-0. Epub 2016 Dec 6.

PMID:
27924615
25.

Classifying pharmacists' interventions recorded in observational databases: Are they all necessary and appropriate?

Charpiat B, Bedouch P, Tod M, Allenet B.

Res Social Adm Pharm. 2017 Nov;13(6):1184-1185. doi: 10.1016/j.sapharm.2016.10.020. Epub 2016 Nov 18.

PMID:
27888092
26.

Feasibility and Utility of the Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.

Linares OA, Tod M, Daly AL, Boston RC.

Clin J Pain. 2016 Dec;32(12):1106-1107. No abstract available.

PMID:
27824618
27.

[Interaction between amoxicillin clavulanic acid and fluindione: Two case reports].

Farnier E, Charhon N, Papillon L, Tod M.

Therapie. 2016 Oct 19. pii: S0040-5957(16)30056-7. doi: 10.2515/therapie/2015059. [Epub ahead of print] French. No abstract available.

PMID:
27771106
28.

Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor Sizes.

Pierrillas PB, Tod M, Amiel M, Chenel M, Henin E.

AAPS J. 2016 Sep;18(5):1262-1272. doi: 10.1208/s12248-016-9936-8. Epub 2016 Jun 21.

PMID:
27329303
29.

[Identification of knowledge deficits of pharmacy students at the beginning of the fifth year of pharmacy practice experience: Proposals to change the content of academic programs].

Charpiat B, Derfoufi S, Larger M, Janoly-Dumenil A, Mouchoux C, Allenet B, Tod M, Grassin J, Boulieu R, Catala O, Bedouch P, Goudable J, Vinciguerra C.

Ann Pharm Fr. 2016 Sep;74(5):404-12. doi: 10.1016/j.pharma.2016.01.001. Epub 2016 Mar 2. French.

PMID:
26944892
30.

Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.

Gabriel L, Tod M, Goutelle S.

Clin Pharmacokinet. 2016 Aug;55(8):977-90. doi: 10.1007/s40262-016-0371-x.

PMID:
26936044
31.

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings.

Wilson S, Tod M, Ouerdani A, Emde A, Yarden Y, Adda Berkane A, Kassour S, Wei MX, Freyer G, You B, Grenier E, Ribba B.

CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):720-7. doi: 10.1002/psp4.12045. Epub 2015 Dec 11.

32.

Response: Is It Truly the Answer? Personalized Oxycodone Dosing Based on Pharmacogenetic Testing and Corresponding Pharmacokinetics.

Linares OA, Tod M, Daly AL, Boston RC.

Pain Med. 2016 Mar;17(3):616-619. Epub 2016 Jan 6. No abstract available.

PMID:
26814313
33.

Implementing and Improving Automated Electronic Tumor Molecular Profiling.

Rioth MJ, Staggs DB, Hackett L, Haberman E, Tod M, Levy M, Warner J.

J Oncol Pract. 2016 Mar;12(3):e332-7. doi: 10.1200/JOP.2015.008276. Epub 2016 Jan 26.

34.

Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen Increases.

de Charry F, Colomban O, You B, Ruffion A, Paparel P, Wilbaux M, Tod M, Freyer G, Perrin P.

Clin Genitourin Cancer. 2016 Jun;14(3):210-217.e1. doi: 10.1016/j.clgc.2015.12.006. Epub 2015 Dec 18.

PMID:
26804605
35.

Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller Tumors.

Pierrillas PB, Tod M, Amiel M, Chenel M, Henin E.

AAPS J. 2016 Mar;18(2):404-15. doi: 10.1208/s12248-015-9862-1. Epub 2016 Jan 12.

36.

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.

Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chêne G; ANRS 129 BKVIR Trial Group.

J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384. Epub 2015 Dec 17.

PMID:
26679250
37.

[Interaction between Amoxicillin Clavulanic Acid and Fluindione: Two Case Reports].

Farnier E, Charhon N, Papillon L, Tod M.

Therapie. 2015 Nov 6. [Epub ahead of print] French.

PMID:
26544165
38.

Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).

You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Hénin E, Guitton J, Tod M, Freyer G.

Cancer Chemother Pharmacol. 2015 Nov;76(5):939-48. doi: 10.1007/s00280-015-2866-9. Epub 2015 Sep 21.

PMID:
26391155
39.

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.

Wilbaux M, Tod M, De Bono J, Lorente D, Mateo J, Freyer G, You B, Hénin E.

CPT Pharmacometrics Syst Pharmacol. 2015 May;4(5):277-85. doi: 10.1002/psp4.34. Epub 2015 Apr 24.

40.

Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.

Bourmaud A, Henin E, Tinquaut F, Regnier V, Hamant C, Colomban O, You B, Ranchon F, Guitton J, Girard P, Freyer G, Tod M, Rioufol C, Trillet-Lenoir V, Chauvin F.

BMC Res Notes. 2015 Jul 4;8:291. doi: 10.1186/s13104-015-1231-8.

41.

A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.

Steelandt J, Jean-Bart E, Goutelle S, Tod M.

Clin Pharmacokinet. 2015 Dec;54(12):1245-58. doi: 10.1007/s40262-015-0288-9.

PMID:
26070946
42.

Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial.

El-Madani M, Hénin E, Lefort T, Tod M, Freyer G, Cassier P, Valette PJ, Rodriguez-Lafrasse C, Berger F, Guitton J, Lachuer J, Slimane K, Barrois C, You B.

Future Oncol. 2015;11(10):1511-8. doi: 10.2217/fon.15.49.

PMID:
25963428
43.

Quantitative methods for prediction of the effect of cytochrome P450 gene polymorphisms on substrate drug exposure.

Goutelle S, Tod M.

Clin Pharmacokinet. 2015 Mar;54(3):319-20. doi: 10.1007/s40262-014-0217-3. No abstract available.

PMID:
25559340
44.

Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid.

Jullien V, Chhun S, Rey E, Dulac O, Tod M, Chiron C, Pons G.

Clin Pharmacokinet. 2015 May;54(5):527-36. doi: 10.1007/s40262-014-0223-5.

PMID:
25503589
45.

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.

Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M, Tod M, Alexandre J, Loriot MA, Goldwasser F, Blanchet B.

Invest New Drugs. 2015 Feb;33(1):257-68. doi: 10.1007/s10637-014-0178-2. Epub 2014 Oct 25.

PMID:
25344452
46.

Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data.

Loue C, Tod M.

AAPS J. 2014 Nov;16(6):1309-20. doi: 10.1208/s12248-014-9663-y. Epub 2014 Oct 2.

47.

Consequences of renal failure on non-renal clearance of drugs.

Lalande L, Charpiat B, Leboucher G, Tod M.

Clin Pharmacokinet. 2014 Jun;53(6):521-32. doi: 10.1007/s40262-014-0146-1. Review.

PMID:
24861189
48.

Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development.

Wilbaux M, Hénin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B.

Gynecol Oncol. 2014 Jun;133(3):460-6. doi: 10.1016/j.ygyno.2014.04.003. Epub 2014 Apr 12.

PMID:
24726614
49.

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients.

Wilbaux M, Hénin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B.

Br J Cancer. 2014 Mar 18;110(6):1517-24. doi: 10.1038/bjc.2014.75. Epub 2014 Feb 20.

50.

Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach.

Gérard C, Stocco J, Hulin A, Blanchet B, Verstuyft C, Durand F, Conti F, Duvoux C, Tod M.

AAPS J. 2014 May;16(3):379-91. doi: 10.1208/s12248-014-9577-8. Epub 2014 Feb 14.

Supplemental Content

Support Center